Travere Therapeutics, Inc.TVTXNASDAQ

Revenue (LTM)

$491M

+110.5% YoY

Net Income (LTM)

$-50M

+84.4% YoY

Free Cash Flow

$38M

Revenue CAGR (5Y)

+38.9%

Marginsdeclining

FCFTurned positive

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	132	109↓17.0%	145↑32.7%	233↑60.5%	491↑110.5%
Gross Profit	128	105↓17.9%	134↑27.4%	225↑68.5%	420↑86.2%
Operating Income	-199	-320↓60.4%	-388↓21.4%	-324↑16.6%	-63↑80.6%
Net Income	-180	-278↓54.6%	-111↑60.0%	-322↓188.6%	-50↑84.4%
EBITDA	-184	-299↓62.3%	-326↓9.0%	-266↑18.5%	22↑108.4%
EPS Diluted	-3.01	-4.37↓45.2%	-1.50↑65.7%	-4.08↓172.0%	-0.56↑86.3%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	166	62↓62.8%	58↓5.7%	59↑0.6%	93↑58.9%
Total Current Assets	583	486↓16.5%	617↑26.8%	417↓32.4%	438↑5.0%
Total Assets	777	673↓13.4%	789↑17.3%	594↓24.7%	605↑1.9%
Total Current Liabilities	124	142↑14.6%	178↑25.1%	201↑12.8%	160↓20.3%
Total Liabilities	475	630↑32.7%	588↓6.6%	535↓9.0%	490↓8.4%
Total Equity	302	43↓85.8%	201↑368.6%	59↓70.6%	115↑94.4%
Total Debt	262	407↑55.5%	405↓0.7%	402↓0.8%	329↓18.1%
Net Debt	96	346↑259.3%	347↑0.2%	343↓1.0%	236↓31.3%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-15	-186↓1159.4%	-280↓50.3%	-237↑15.2%	38↑115.9%
Capital Expenditure	-24	-28↓17.5%	-42↓46.6%	-101↓143.4%	0
Free Cash Flow	-39	-215↓451.2%	-322↓49.8%	-339↓5.3%	38↑111.2%
Stock-Based Comp	30	38↑29.0%	44↑16.0%	37↓16.6%	45↑21.6%
Net Change in Cash	81	-104↓228.5%	-4↑96.6%	0↑110.2%	35↑9510.0%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance